menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Biocon Biologics and Civica Expand Insulin Aspart Access in

    PR NEWSWIRE

    Biocon`s Yesintek Ph3 Data Shows Efficacy In Plaque Psoriasis

    PR NEWSWIRE

    Biocon launches diabetes, obesity management drug in UK

    ECONOMICTIMES

    Biocon Biologics launches Yesintek Biosimilar to Stelara in US

    INDPHARMAPOST

    Europe approves Biocon Biologics` Ustekinumab Biosimilar

    INDPHARMAPOST

    India`s Biocon plans IPO for biosimilars business by March 2026

    REUTERS

    Biocon`s Q3 revenue dips, banks on obesity drugs for future growth

    REUTERS

    Biocon urges gov to exempt cancer, rare-disease drugs from tax

    REUTERS

    US FDA classifies Biocon Biologics site as VAI

    EXPRESSPHARMA

    Biocon Biologics to Present at J.P. Morgan Healthcare Conference

    PR NEWSWIRE

    Japan Health Authority approves Biocon Ustekinumab BS

    INDIANPHARMAPOST

    Biocon Biologics embarks on a three-stage strategic journey

    INDPHARMAPOST

    Biocon completes 1 year as integrated global biosimilars enterprise

    EXPRESSPHARMA

    Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

    INDPHARMAPOST

    Biocon Biologics receives FDA approval for biosimilar YESINTEK

    EXPRESSPHARMA

    Biocon Biologic Supports Diabetes Africa To Embed Nurses In Ethiopia

    EXPRESSPHARMA

    Biocon Biologics looks to trim $300 million debt in 1 year

    ECONOMICTIMES

    Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics

    BUSINESS STD

    Biocon Biologics` Bengaluru Unit Receives Voluntary FDA Action

    ECONOMICTIMES

    Biocon refinances $ 1.1 bn long-term debt through USD bonds

    EXPRESSPHARMA

    USFDA Completes Inspection At Biocon Biologics’ Insulin Facility

    INDPHARMAPOST

    Biocon signs agreement with Tabuk Pharma for GLP-1 products

    EXPRESSPHARMA

    Biocon Global to raise funds through senior secured notes

    INDPHARMAPOST

    Biocon Biologics to Present Dermatology Data at EADV Congress 2024

    PR NEWSWIRE

    FDA Issues Form 483 to Biocon Biologics Limited

    FDA

    EMA approves Biocon Biologics’ new mAbs facility in India

    INDIANPHARMAPOST

    Biocon Gets US Approval For Biosimilar Aflibercept Yesafili

    PR NEWSWIRE

    USFDA approves Biocon Biologics` biosimilar product to treat ophthalmology

    ECONOMICTIMES

    Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

    INDINPHARMAPOST

    US FDA approves two biosimilars for blockbuster eye drug Eylea

    REUTERS

    Biocon Biologics’ Yesafili (aflibercept-jbvf) Receives Approval In U.S

    FDA

    Biocon Biologics gears up to challenge Stelara in the US

    FIERCE PHARMA

    Biocon Biologics focusing on market share gains of biosimilars in key markets

    ECONOMIC TIMES

    Biocon Concludes Integration of Biosimilars Business in 120 countries

    PR NEWSWIRE

    Biocon Biologics recognized as an Asia IP Elite for 2023

    INDIAN PHARMA POST

    Biocon Biologics Completes Integration of Viatris™ Biosimilar Business

    GLOBENEWSWIRE

    Biocon Biologics receives MHRA Approval for Biosimilar Aflibercept ‘Yesafili’

    INDIAN PHARMA POST

    Biocon Biologics announces divestment of two non-core branded formulations

    INDIAN PHARMA POST

    Biocon Biologics names Kedar Upadhye as new CFO

    ECONOMIC TIMES

    Biocon`s Malaysia insulin facility classified by FDA for official action

    ECONOMIC TIMES

    On track to integrate major part Viatris``acquired biosimilars biz this fiscal

    ECONOMICTIMES

    Biocon facility in Malaysia found to have issues once again by the FDA

    ENDPTS

    Biocon Biologics to integrate Viatris` US biosimilar business by Q2 end`

    ECONOMIC TIMES

    Competition Commission of India clears Kotak-Biocon Biologics deal

    ECONOMIC TIMES

    Biocon Biologics announces top leadership appointments

    ECONOMIC TIMES

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.